- Previous Close
4.2400 - Open
4.0500 - Bid 4.1700 x --
- Ask 4.2000 x --
- Day's Range
4.1100 - 4.2500 - 52 Week Range
1.9600 - 8.9750 - Volume
560,831 - Avg. Volume
1,621,659 - Market Cap (intraday)
1.338B - Beta (5Y Monthly) 1.68
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1600 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
8.67
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development and clinical stage radiopharmaceuticals products in Australia and the United States. The company's products include SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2; developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. It develops theranostic therapy and imaging products for the treatment of cancer in children and adults. The company was incorporated in 2010 and is based in Sydney, Australia.
www.claritypharmaceuticals.comRecent News: CU6.AX
View MorePerformance Overview: CU6.AX
Trailing total returns as of 12/31/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CU6.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CU6.AX
View MoreValuation Measures
Market Cap
1.34B
Enterprise Value
1.20B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
9.14
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-24.19%
Return on Equity (ttm)
-39.29%
Revenue (ttm)
11.51M
Net Income Avi to Common (ttm)
-42.32M
Diluted EPS (ttm)
-0.1600
Balance Sheet and Cash Flow
Total Cash (mrq)
136.51M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-29.52M